“We see the reward as positively skewed on a risk-adjusted basis,” analysts at Leerink Partners wrote, citing improving trends in Aetna and Health Care Benefits (HCB). The firm noted that CVS ...
Leerink analyst Michael Cherny upgraded CVS Health (CVS) to Outperform from Market Perform with a price target of $75, up from $55. The firm ...
“We see the reward as positively skewed on a risk-adjusted basis,” analysts at Leerink Partners wrote, citing improving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback